S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$6.91
+0.3%
$9.54
$2.09
$14.84
$489.85M0.055.50 million shs3.59 million shs
UiPath Inc. stock logo
PATH
UiPath
$18.74
-1.6%
$22.97
$12.38
$27.87
$10.66B0.968.92 million shs5.60 million shs
ROI
RiskOn International
$0.12
+3.6%
$0.12
$0.10
$7.19
$3.97M1.0810.92 million shs5.37 million shs
Veris Residential, Inc. stock logo
VRE
Veris Residential
$14.43
+1.8%
$14.85
$13.06
$18.98
$1.33B1.23682,212 shs595,584 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
-2.13%-17.98%-21.17%-25.51%+15.41%
UiPath Inc. stock logo
PATH
UiPath
-0.44%-10.68%-17.65%-14.41%+19.72%
ROI
RiskOn International
0.00%0.00%0.00%-21.92%+12,179,900.00%
Veris Residential, Inc. stock logo
VRE
Veris Residential
+1.14%-3.61%-3.54%-9.08%-9.75%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Altimmune, Inc. stock logo
ALT
Altimmune
1.1158 of 5 stars
3.32.00.00.01.71.70.0
UiPath Inc. stock logo
PATH
UiPath
3.8992 of 5 stars
4.34.00.00.02.74.20.6
ROI
RiskOn International
N/AN/AN/AN/AN/AN/AN/AN/A
Veris Residential, Inc. stock logo
VRE
Veris Residential
2.558 of 5 stars
2.34.01.70.02.02.51.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
2.67
Moderate Buy$15.00122.22% Upside
UiPath Inc. stock logo
PATH
UiPath
2.50
Moderate Buy$27.4145.96% Upside
ROI
RiskOn International
N/AN/AN/AN/A
Veris Residential, Inc. stock logo
VRE
Veris Residential
2.67
Moderate Buy$17.0018.22% Upside

Current Analyst Ratings

Latest ROI, ALT, VRE, DTS, and PATH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/9/2024
Veris Residential, Inc. stock logo
VRE
Veris Residential
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$15.00 ➝ $14.00
4/8/2024
UiPath Inc. stock logo
PATH
UiPath
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$27.00
4/1/2024
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
4/1/2024
UiPath Inc. stock logo
PATH
UiPath
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$29.00
3/28/2024
Altimmune, Inc. stock logo
ALT
Altimmune
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
3/20/2024
UiPath Inc. stock logo
PATH
UiPath
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00
3/20/2024
UiPath Inc. stock logo
PATH
UiPath
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$29.00
3/20/2024
UiPath Inc. stock logo
PATH
UiPath
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
3/15/2024
UiPath Inc. stock logo
PATH
UiPath
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$23.00 ➝ $25.00
3/15/2024
UiPath Inc. stock logo
PATH
UiPath
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$27.00 ➝ $30.00
3/14/2024
UiPath Inc. stock logo
PATH
UiPath
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$26.00 ➝ $30.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$430K1,112.81N/AN/A$2.75 per share2.45
UiPath Inc. stock logo
PATH
UiPath
$1.31B8.17N/AN/A$3.54 per share5.31
ROI
RiskOn International
$30K132.48N/AN/A($0.42) per share-0.29
Veris Residential, Inc. stock logo
VRE
Veris Residential
$279.86M4.74N/AN/A$13.88 per share1.04

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$88.45M-$1.65N/AN/AN/A-20,780.75%-44.77%-40.72%5/9/2024 (Estimated)
UiPath Inc. stock logo
PATH
UiPath
-$89.88M-$0.17N/A939.00N/A-6.87%-3.29%-2.36%5/22/2024 (Estimated)
ROI
RiskOn International
-$81.63MN/A0.00N/AN/A-533.91%-450.39%5/21/2024 (Estimated)
Veris Residential, Inc. stock logo
VRE
Veris Residential
-$107.26M-$1.23N/A25.232.70-38.30%-11.53%-4.32%4/24/2024 (Confirmed)

Latest ROI, ALT, VRE, DTS, and PATH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/24/2024N/A
Veris Residential, Inc. stock logo
VRE
Veris Residential
$0.11N/A-$0.11N/AN/AN/A  
3/13/2024Q4 2024
UiPath Inc. stock logo
PATH
UiPath
-$0.04$0.06+$0.10$0.06$383.32 million$405.25 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
UiPath Inc. stock logo
PATH
UiPath
N/AN/AN/AN/AN/A
ROI
RiskOn International
N/AN/AN/AN/AN/A
Veris Residential, Inc. stock logo
VRE
Veris Residential
$0.211.46%-44.51%N/A N/A

Latest ROI, ALT, VRE, DTS, and PATH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/29/2024
Veris Residential, Inc. stock logo
VRE
Veris Residential
Quarterly$0.05201.4%4/2/20244/3/20244/16/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
N/A
17.26
17.26
UiPath Inc. stock logo
PATH
UiPath
N/A
3.63
3.63
ROI
RiskOn International
N/A
0.34
0.34
Veris Residential, Inc. stock logo
VRE
Veris Residential
1.45
1.01
1.01

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
UiPath Inc. stock logo
PATH
UiPath
62.50%
ROI
RiskOn International
5.65%
Veris Residential, Inc. stock logo
VRE
Veris Residential
93.04%

Insider Ownership

CompanyInsider Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
4.10%
UiPath Inc. stock logo
PATH
UiPath
31.03%
ROI
RiskOn International
3.00%
Veris Residential, Inc. stock logo
VRE
Veris Residential
15.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
5970.89 million67.99 millionOptionable
UiPath Inc. stock logo
PATH
UiPath
3,833569.01 million392.45 millionOptionable
ROI
RiskOn International
1632.63 million31.66 millionN/A
Veris Residential, Inc. stock logo
VRE
Veris Residential
19792.23 million78.40 millionOptionable

ALT, ROI, VRE, DTS, and PATH Headlines

SourceHeadline
Veris Residential (VRE) Scheduled to Post Earnings on WednesdayVeris Residential (VRE) Scheduled to Post Earnings on Wednesday
americanbankingnews.com - April 17 at 3:10 AM
Veris Residential, Inc. Announces Dates for First Quarter 2024 Financial Results and WebcastVeris Residential, Inc. Announces Dates for First Quarter 2024 Financial Results and Webcast
finance.yahoo.com - April 15 at 10:21 AM
Veris Residential, Inc. (NYSE:VRE) Short Interest Down 27.4% in MarchVeris Residential, Inc. (NYSE:VRE) Short Interest Down 27.4% in March
marketbeat.com - April 12 at 2:50 PM
Veris Residential (NYSE:VRE) Price Target Lowered to $14.00 at Truist FinancialVeris Residential (NYSE:VRE) Price Target Lowered to $14.00 at Truist Financial
americanbankingnews.com - April 10 at 3:26 AM
Truist Financial Lowers Veris Residential (NYSE:VRE) Price Target to $14.00Truist Financial Lowers Veris Residential (NYSE:VRE) Price Target to $14.00
marketbeat.com - April 9 at 2:26 PM
Veris Residential (NYSE:VRE) Trading 5.8% Higher Veris Residential (NYSE:VRE) Trading 5.8% Higher
marketbeat.com - April 8 at 1:45 PM
Veris Residential Declares Quarterly Cash DividendVeris Residential Declares Quarterly Cash Dividend
prnewswire.com - February 29 at 5:26 PM
Veris Residential beats top-line and bottom-line estimates; initiates FY24 outlookVeris Residential beats top-line and bottom-line estimates; initiates FY24 outlook
msn.com - February 22 at 10:44 AM
Veris Residential, Inc. 2023 Q4 - Results - Earnings Call PresentationVeris Residential, Inc. 2023 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 22 at 8:50 AM
Veris Residential (VRE) Surpasses Q4 FFO and Revenue EstimatesVeris Residential (VRE) Surpasses Q4 FFO and Revenue Estimates
finance.yahoo.com - February 21 at 11:28 PM
Veris Residential, Inc. Reports Fourth Quarter and Full Year 2023 ResultsVeris Residential, Inc. Reports Fourth Quarter and Full Year 2023 Results
finance.yahoo.com - February 21 at 11:28 PM
Compared to Estimates, Veris (VRE) Q4 Earnings: A Look at Key MetricsCompared to Estimates, Veris (VRE) Q4 Earnings: A Look at Key Metrics
zacks.com - February 21 at 9:30 PM
Veris Residential (VRE) Surpasses Q4 FFO and Revenue EstimatesVeris Residential (VRE) Surpasses Q4 FFO and Revenue Estimates
zacks.com - February 21 at 8:41 PM
Veris Residential, Inc. Reports Fourth Quarter and Full Year 2023 ResultsVeris Residential, Inc. Reports Fourth Quarter and Full Year 2023 Results
prnewswire.com - February 21 at 7:04 PM
Veris Residential Inc (VRE) Reports Solid Growth in Core FFO and NOI for FY 2023Veris Residential Inc (VRE) Reports Solid Growth in Core FFO and NOI for FY 2023
finance.yahoo.com - February 21 at 6:28 PM
Veris Residential, Inc. Announces Dates for Fourth Quarter 2023 Financial Results and WebcastVeris Residential, Inc. Announces Dates for Fourth Quarter 2023 Financial Results and Webcast
finance.yahoo.com - February 7 at 3:57 PM
VRE Stock Sees Decline of Approximately -2.24% in Last Five DaysVRE Stock Sees Decline of Approximately -2.24% in Last Five Days
knoxdaily.com - February 1 at 2:13 PM
Veris Residential Announces Tax Treatment of 2023 DistributionsVeris Residential Announces Tax Treatment of 2023 Distributions
finance.yahoo.com - January 22 at 11:01 AM
An Analysis of Veris Residential Inc (VRE)’s Potential Price GrowthAn Analysis of Veris Residential Inc (VRE)’s Potential Price Growth
knoxdaily.com - January 3 at 8:16 PM
Veris Residential Stock (NYSE:VRE) Dividends: History, Yield and DatesVeris Residential Stock (NYSE:VRE) Dividends: History, Yield and Dates
benzinga.com - January 1 at 10:22 AM
Veris Residential Declares Quarterly Cash DividendVeris Residential Declares Quarterly Cash Dividend
finance.yahoo.com - December 18 at 10:59 PM
Veris Residential Recognized as a Leader in ESG, DEI and Corporate Stewardship by Top Real Estate and Business OrganizationsVeris Residential Recognized as a Leader in ESG, DEI and Corporate Stewardship by Top Real Estate and Business Organizations
finance.yahoo.com - November 16 at 1:46 PM
Recent Insider Activity Could Benefit Veris Residential Inc (VRE)Recent Insider Activity Could Benefit Veris Residential Inc (VRE)
knoxdaily.com - November 6 at 2:57 PM
Veris Residential, Inc. (NYSE:VRE) Q3 2023 Earnings Call TranscriptVeris Residential, Inc. (NYSE:VRE) Q3 2023 Earnings Call Transcript
insidermonkey.com - October 28 at 1:10 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Altimmune logo

Altimmune

NASDAQ:ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
UiPath logo

UiPath

NYSE:PATH
UiPath Inc. provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization. Its platform combines artificial intelligence with desktop recording, back-end mining of both human activity and system logs, and intuitive visualization tools, which enables users to discover, analyze, and identify processes to automate in a centralized portal; offers low-code development environments that allows users in an organization to create attended and unattended automations without any prior knowledge of coding; deploys robots in highly immersive attended experiences or in standalone, unattended modes behind the scenes, and can leverage native connectors built for commonly used line-of-business applications; offers centralized tools designed to manage, test, and deploy automations and ML models across the enterprise; allows customers to manage long running processes that orchestrate work between robots and humans; and enable users to track, measure, and forecast the performance of automation in their enterprise and help businesses ensure compliance with business standards. In addition, the company provides maintenance and support for its software, as well as professional services, such as training and implementation services to facilitate the adoption of its platform. It serves banking, healthcare, financial services, and government entities. UiPath Inc. has collaboration with Deloitte to introduce Turnkey automation offering for growth companies. The company was founded in 2005 and is headquartered in New York, New York.

RiskOn International

NASDAQ:ROI
RiskOn International, Inc., through its subsidiaries, owns and operates gaming platform in the United States. It also owns and operates bitnile.com metaverse platform, a social networking community that allows users to engage and purchase digital and physical products while playing 3D immersive games. The company offers virtual markets, a graphic product that changes the appearance of characters in virtual real estate, digital art, and other collectibles; sweepstakes gaming, a gaming zone for virtual and real money prizes; building private spaces, a design option that allows users to construct and customize their dream homes or private spaces; and real and virtual concerts, a concert for users. In addition, it provides fashion, electronics, and home related goods for marketplaces; organizes competitions for users, as well as enables users to interact with individuals with socialization and connectivity related products. Further, the company offers gaming options for users, sweepstakes, and social gaming experience users. The company was formerly known as BitNile Metaverse, Inc. and changed its name to RiskOn International, Inc. in November 2023. RiskOn International, Inc. was founded in 2011 and is headquartered in San Antonio, Texas.
Veris Residential logo

Veris Residential

NYSE:VRE
Veris Residential, Inc. is a forward-thinking, environmentally and socially conscious real estate investment trust (REIT) that primarily owns, operates, acquires and develops holistically-inspired, Class A multifamily properties that meet the sustainability-conscious lifestyle needs of today's residents while seeking to positively impact the communities it serves and the planet at large. The company is guided by an experienced management team and Board of Directors and is underpinned by leading corporate governance principle; a best-in-class and sustainable approach to operations; and an inclusive culture based on equality and meritocratic empowerment.